We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Crescendo Biologics and Cancer Research UK have entered into a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.